Stock Analysis

Lonza Group Full Year 2024 Earnings: EPS Misses Expectations

SWX:LONN
Source: Shutterstock
Advertisement

Lonza Group (VTX:LONN) Full Year 2024 Results

Key Financial Results

  • Revenue: CHF6.57b (down 2.1% from FY 2023).
  • Net income: CHF636.0m (down 2.8% from FY 2023).
  • Profit margin: 9.7% (in line with FY 2023).
  • EPS: CHF8.93.
earnings-and-revenue-growth
SWX:LONN Earnings and Revenue Growth January 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Lonza Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 23%.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Switzerland.

Performance of the Swiss Life Sciences industry.

The company's shares are up 1.3% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Lonza Group's balance sheet health.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SWX:LONN

Lonza Group

Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.

Excellent balance sheet with reasonable growth potential.

Advertisement